Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NOS3 | P29474 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | NOS2 | P35228 | 2/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7108845 | 1.00 | SLC7A5 (0.54) | SLC7A5ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL3770254 | 1.00 | SLC7A5 (0.54) | SLC7A5ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL28637433 | 0.84 | SLC7A5 (0.54) | SLC7A5ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL30547274 | 0.84 | GRIA2 (0.56) | SLC7A5ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL5869551 | 0.84 | GRIA2 (0.56) | SLC7A5ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL30831490 | 0.84 | GRIA2 (0.56) | SLC7A5ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL1816260 | 0.84 | GRIA2 (0.56) | SLC7A5ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL2580149 | 0.84 | GRIA2 (0.56) | SLC7A5ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL31505896 | 0.84 | GRIA2 (0.56) | SLC7A5ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL19699296 | 0.84 | SLC7A5 (0.54) | SLC7A5ALDH1A1NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345669-B2 | Urea derivatives and methods of use thereof | NodThera Limited (GB) | 2022-05-31 | — | — | US | disclosed |
| US-20200131141-A1 | CHEMICAL COMPOUNDS | NodThera Limited (GB) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131141-A1 | CHEMICAL COMPOUNDS | IL1B, CASP1, IL1A | SLC7A5 4162/4885ALDH1A1 325/4885NOS3 443/4885 |
| US-11345669-B2 | Urea derivatives and methods of use thereof | IL1B, IL1A, NOD1 | SLC7A5 4115/4885ALDH1A1 397/4885NOS3 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.